The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

Eligible for this study are patients with stage III NSCLC (8th edition TNM Classification) who (are about to) start(ed) follow-up care (which may include adjuvant treatment) at a participating hospital. Patients may already be included during their curative intent treatment. Patients enter a screening period that runs until their randomization. Inclusion Criteria: To be eligible to participate in this study, a subject must meet all of the following criteria at the timing of randomization: * Cytological or histologically proven stage III non-small cell lung cancer before start of curative intent treatment * Treated with curative intent and started follow-up care * All adjuvant treatments are permitted as co-intervention during follow-up care * Age 18 years or older * ECOG Performance Status classification 0-2 at moment of inclusion * Written and signed informed consent by the patient or patient's representative (with the understanding that consent may be withdrawn by the patient or patient's representative at any time without consequences to future medical care) Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: * Life expectancy shorter than 6 months at the end of curative intent treatment * Evidence of recurrence after end of curative intent treatment and before randomization (4 months follow-up) * Any condition that, in the opinion of the investigator, would interfere with evaluation of the intervention or interpretation of HRQOL or other study results.